Effects of simvastatin 20 mg/d on serum lipid profiles in Japanese hyperlipidemic patients: A prospective, open-label pilot study

Current Therapeutic Research - Clinical and Experimental

Volumn 66, Issue 6, 2005, Pages 613-629

  Yoshida, Hiroshi ^a   Yanai, Hidekatsu ^a   Shoda, Toru ^a   Furutani, Nobuyuki ^a   Sato, Noriko ^a   Tada, Norio ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

2002 Japanese Atherosclerosis Society guideline; Japanese hyperlipidemic patients; Lipid goal; Low high density lipoprotein cholesterol; Simvastatin 20 mg

Indexed keywords

CHOLESTEROL; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33244466348     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2005.12.008     Document Type: Article

References (50)

1. Anderson K.M., Castelli W.P., and Levy D. Cholesterol and mortality. 30 Years of follow-up from the Framingham study JAMA 257 1987 2176 2180
2. Durrington P. Dyslipidaemia Lancet 362 2003 717 731
3. Gotto A.M. Jr Treating hypercholesterolemia: Looking forward Clin Cardiol 26 Suppl 1 2003 121 128
4. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) JAMA 269 1993 3015 3023
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
6. Shepherd J., Cobbe S.M., Ford I. West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995 Atheroscler Suppl. 5 2004 91 97
7. Downs J.R., Clearfield M., and Weis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
9. Sacks F.M., Pfeffer M.A., and Moye L.A. Cholesterol and Recurrent Events Trial Investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
10. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
11. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial Lancet 360 2002 7 22
12. Nissen S.E., Tuzcu E.M., and Schoenhagen P. REVERSAL Investigators Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial JAMA 291 2004 1071 1080
13. Cannon C.P., Braunwald E., and McCabe C.H. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
14. Bellosta S., Paoletti R., and Corsini A. Safety of statins: Focus on clinical pharmacokinetics and drug interactions Circulation 109 Suppl 1 2004 50 57
15. Davidson M.H., and National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP)-ATP III Guidelines A look to the future: New treatment guidelines and a perspective on statins Am J Med 112 Suppl 8A 2002 34S 41S
16. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and metaanalysis BMJ 326 2003 1423
17. Gotto A.M. Jr Risks and benefits of continued aggressive statin therapy Clin Cardiol 26 Suppl 3 2003 3 12
18. Japan Atherosclerosis Society (JAS) guidelines for diagnosis and treatment of atherosclerotic cardiovascular disease 2002 JAS Tokyo, Japan
19. Strutt K., Caplan R., and Hutchinson H. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy Circ J 68 2004 107 113
20. Yoshida H., Ishikawa T., and Ayaori M. Effect of low-dose simvastatin on cholesterol levels, oxidative susceptibility, and antioxidant levels of low-density lipoproteins in patients with hypercholesterolemia: A pilot study Clin Ther 17 1995 379 389
21. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
22. Conti M., Morand P.C., Levillain A., and Lemonnier A. Improved fluorometric determination of malonaldehyde Clin Chem 37 1991 1273 1275
23. Gordon T., Castelli W.P., and Hjortland M.C. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am J Med 62 1977 707 714
24. Anderson K.M., Odell P.M., Wilson P.W., and Kannel W.B. Cardiovascular disease risk profiles Am Heart J 121 1991 293 298
25. Wilson P.W., D'Agostino R.B., and Levy D. Prediction of coronary heart disease using risk factor categories Circulation 97 1998 1837 1847
26. Linton M.F., Fazio S., and National Cholesterol Education Program (NCEP)-the Third Adult Treatment Panel (ATPIII) A practical approach to risk assessment to prevent coronary artery disease and its complications Am J Cardiol 92 2003 19 26
27. Chobanian A.V., Bakris G.L., and Black H.R. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National Heart, Lung, and Blood Institute, and the National High Blood Pressure Education Program Coordinating Committee Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) Hypertension 42 2003 1206 1252
28. American Diabetes Association, Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Clinical practice recommendations 2002 Diabetes Care 25 Suppl 1 2002 S1 S147
29. Pearson T.A., Laurora I., Chu H., and Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Arch Intern Med 160 2000 459 467
30. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) JAMA 269 1993 3015 3023
31. Matsuzaki M., Kita T., Mabuchi H. J-LIT Study Group (Japan Lipid Intervention Trial) Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia Circ J 66 2002 1087 1095
32. Jones P.H., Davidson M.H., Stein E.A. STELLAR Study Group Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) Am J Cardiol 92 2003 152 160
33. Saito Y., Goto Y., and Dane A. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia J Atheroscler Thromb 10 2003 329 336
34. Stein D.T., Devaraj S., and Balis D. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia Arterioscler Thromb Vasc Biol 21 2001 2026 2031
35. Chong P.H., Kezele R., and Franklin C. High-density lipoprotein cholesterol and the role of statins Circ J 66 2002 1037 1044
36. Toth J.P. High-density lipoprotein and cardiovascular risk Circulation 109 2004 1809 1812
37. Despres J.P., Lemieux I., and Dagenais G.R. HDL-cholesterol as a marker of coronary heart disease risk: The Quebec cardiovascular study Atherosclerosis 153 2000 263 272
38. Assmann G., and Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster Study Am J Cardiol 70 1992 733 737
39. Assmann G., and Schulte H. Modelling the Helsinki Heart Study by means of risk equations from the PROCAM Study and the Framingham Heart Study Drugs 40 Suppl 1 1990 13 18
40. Ballantyne C.M., Blazing M.A., and Hunninghake D.B. Effect of high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hyper- cholesterolemia: Results of the Comparative HDL Efficacy and Safety Study (CHESS) Am Heart J 146 2003 862 869
41. Martin G., Duez H., and Blanquart C. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I J Clin Invest 107 2001 1423 1432
42. Lamarche B., Rashid S., and Lewis G.F. HDL metabolism in hypertriglyceridemic states: An overview Clin Chim Acta 286 1999 145 161
43. Ginsberg H.N. New perspectives on atherogenesis: Role of abnormal triglyceride-rich lipoprotein metabolism Circulation 106 2002 2137 2142
44. Miesenbock G., Holzl B., and Foger B. Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities J Clin Invest 91 1993 448 455
45. Tall A.R., Jiang X., Luo Y., and Silver D. George Lyman Duff memorial lecture: Lipid transfer proteins, HDL metabolism, and atherogenesis Arterioscler Thromb Vasc Biol 20 2000 1185 1188
46. Packard C.J., and Saito Y. Non-HDL cholesterol as a measure of atherosclerotic risk J Atheroscler Thromb 11 2004 6 14
47. Chait A., Brazg R.L., Tribble D.L., and Krauss R.M. Susceptibility of small, dense, low-density lipoprotein to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B Am J Med 94 1993 350 356
48. Yoshida H., Ishikawa T., and Ayaori M. Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: A randomized, double-blind, placebo-controlled study Atherosclerosis 139 1998 179 187
49. Mertens A., and Holvoet P. Oxidized LDL and HDL: Antagonists in atherothrombosis FASEB J 15 2001 2073 2084
50. Balk E.M., Lau J., and Goudas L.C. Effects of statins on nonlipid serum markers associated with cardiovascular disease: A systematic review Ann Intern Med 139 2003 670 682